Neoadjuvant chemoradiotherapy in esophageal cancer: Is it still the question?

Journal of Clinical Oncology

Volumn 26, Issue 31, 2008, Pages 5133-5134

  Pereira, Bruno ^a   Gourgou Bourgade, Sophie ^a   Azria, David ^a   Ychou, Marc ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ESOPHAGUS CANCER; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; HUMANS; NEOADJUVANT THERAPY; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 55549141865     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.0322     Document Type: Letter

References (1)

1. Tepper J, Krasna MJ, Niedzwiecki D, et al: Phase III trial of trimodalidy therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 26:1086-1092, 2008